Logo

Myovant's Ryeqo (relugolix- estradiol- and norethindrone acetate) Receives EC's Approval for the Treatment of Women with Uterine Fibroids

Share this

Myovant's Ryeqo (relugolix- estradiol- and norethindrone acetate) Receives EC's Approval for the Treatment of Women with Uterine Fibroids

Shots:

  • The approval is based on safety & efficacy data from the P-III LIBERTY program that consists of 2 studies i.e LIBERTY 1 & 2 evaluating Ryeqo in adult women with UF with no limitation for a duration of use. The EC's decision is valid in all 27 member states of the EU- Iceland- Norway & Liechtenstein
  • The results showed that the therapy improved the symptoms i.e heavy menstrual bleeding & pain in a woman with UF and showed well-tolerated safety profile
  • In Mar’2020- Myovant & Gedeon Richter collaborate to commercialize relugolix combination tablet for UF & endometriosis in EU- Russia- Latin America- Australia & New Zealand. The MAA for endometriosis is expected to submit in H2’21

  | Ref: GLOBE NEWSWIRE | Image: Myovant Sciences

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions